Clinical Trial Update: Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer [Phase 4]

View source ↗

Summary

This Phase 4 study assesses the pharmacokinetic model of abemaciclib and its correlation with severe diarrhea as the primary toxicity endpoint in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Abemaciclib, Abemaciclib-related Diarrhea | Phase 4 | Status: NOT_YET_RECRUITING